Expand AKBA Menu
AKBA MENU

AKBA Latest Press Releases

-- September 14, 2026 --

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases Globe Newswire 8:00 AM

-- September 1, 2026 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston Globe Newswire 8:00 AM

-- August 5, 2026 --

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Globe Newswire 4:05 PM

-- August 3, 2026 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases Globe Newswire 8:00 AM

-- July 29, 2026 --

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights Globe Newswire 8:00 AM

-- July 2, 2026 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 30, 2026 --

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA Globe Newswire 8:00 AM

-- June 10, 2026 --

Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio Globe Newswire 8:00 AM

-- June 1, 2026 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- May 28, 2026 --

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- May 7, 2026 --

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights Globe Newswire 7:00 AM

-- May 4, 2026 --

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology Globe Newswire 8:00 AM

-- April 30, 2026 --

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes